OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Tasadenoturev active in DIPG	964
A new standard of care for advanced-stage urothelial carcinoma	947
From little subclones grow mighty oaks	884
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	764
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	754
Ecological management of the microbiota in patients with cancer	694
Novel ICI–TKI combination improves HCC outcomes	683
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	674
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	590
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	575
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	558
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	525
Hodgkin lymphoma: great progress with room for improvement	493
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	469
Current understanding and management of CAR T cell-associated toxicities	443
Gut microbiota in colorectal cancer development and therapy	415
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	410
The emerging roles of circRNAs in cancer and oncology	402
Contrasting results with second-line CAR T cells in large B cell lymphoma	374
Sacituzumab tirumotecan improves OS in mTNBC	373
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	369
Ponatinib superior to imatinib in Ph+ ALL	363
Mortality is similar with active monitoring	360
From ESMO 2022	342
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	304

Belzutifan as a new option in pheochromocytomas and paragangliomas	276
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	276
Understanding and overcoming multidrug resistance in cancer	273
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	272
Humanized mouse models for immuno-oncology research	269
Harnessing cytokines and chemokines for cancer therapy	268
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	268
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	263
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	259
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	256
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	253
Survival benefit with second-line combination in endometrial cancer	253
Craniospinal irradiation improves leptomeningeal metastasis control	252
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	244
Spatial landscapes of cancers: insights and opportunities	239
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	228
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	225
Improving outcomes in patients with oesophageal cancer	223
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	194
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	192
Biomarkers for immunotherapy of hepatocellular carcinoma	188
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	183
Harnessing big data to characterize immune-related adverse events	183
New CAPSTONE of SCLC therapy?	177
SHINE a light: frontline ibrutinib for MCL	174
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	169
Women with clinically node negative breast cancer can safely avoid axillary surgery	165
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	162
From ESMO 2023: advances in lung cancer	148
DREAMseq of therapy for BRAF-mutant melanoma	148
Prospective comparisons support the use of navigational bronchoscopy	134
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	132
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	132
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’	131
Targeting chromosomal instability in patients with cancer	127
Circulating tumour DNA — looking beyond the blood	123
Long-term outcomes following CAR T cell therapy: what we know so far	120
Mitigating acute chemotherapy-associated adverse events in patients with cancer	117
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	116
Response to neoadjuvant endocrine therapy complements recurrence score	116
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	115
Multiomics STEP up in correlative analysis of response to CAR T cells	114
From the ESMO Congress 2023	113
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	108
Sentinel lymph node biopsy improves surgical management of cervical cancer	106
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	102
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	99
Newly approved cancer drugs in China — innovation and clinical benefit	98
HAIC-FO improves outcomes in HCC	98
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	98

Claudin 18.2 as a novel therapeutic target	94
Lung cancer in patients who have never smoked — an emerging disease	90
Enhancing immunotherapy with tumour-responsive nanomaterials	90
Clinical implications of T cell exhaustion for cancer immunotherapy	89
Combining CAR T cells effective in RRMM	88
Targeted biopsy reduces detection of clinically insignificant cancer	88
T-DXd effective as second-line therapy in G/GEJ cancers	87
Second-line tarlatamab improves OS in SCLC	86
Less-frequent surveillance is noninferior to annual mammography	79
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	78
Barriers in access to oncology drugs — a global crisis	77
Two decades of advances in clinical oncology — lessons learned and future directions	75
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	74
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	73
Translating biological insights into improved management of endometrial cancer	72
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	70
HSCT prolongs remission of high-risk CTCLs	68
BrECADD raises the bar in classical Hodgkin lymphoma	68
Nirogacestat effective in desmoid tumours	67
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	66
Thermal ablation is safer than resection of colorectal liver lesions	64
Promising OS with oncolytic virotherapy	63
Cured but breathless: the growing burden of DIILD in cancer survivors	63
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	62
GPRC5D-CAR T cells active in MM	60
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	58
Promise with co-administration of CAR T cells	57
Non-financial conflicts of interest	57
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	56
Efficacy of TILs confirmed	49
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	48
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	47
Exploiting bacteria for cancer immunotherapy	47
The current state of the art and future trends in RAS-targeted cancer therapies	46
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	46
Neoadjuvant pembrolizumab improves outcomes	44
Repotrectinib effective in ROS1-fusion-positive NSCLC	42
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	41
Belzutifan is active in VHL-related cancers	38
KN046 shows tolerability and activity in TNBC	38
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	37
LAG3 inhibition improves outcomes	37
Problematic crossovers in cancer drug trials	36
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	35
Integrated MRI-guided radiotherapy — opportunities and challenges	34
The emerging roles of γδ T cells in cancer immunotherapy	34
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	30
CAR T cells induce durable remission of neuroblastoma	29
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	26
Axicabtagene effective in indolent NHL	25
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	25
GPRC5D as a novel immunotherapeutic target in multiple myeloma	25
National value-based pricing negotiation for oncology drugs — lessons from China	23
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	23
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	22
Personalizing adjuvant therapy for patients with colorectal cancer	22
Laparoscopic TME is non-inferior	21